Dr Misako Nagasaka speaks to ecancer about taletrectinib versus crizotinib in ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

This trial compares the new drug taletrectinib with crizotinib for treating ROS1 non-small cell lung cancer using matching-adjusted indirect comparison (MAIC) analysis.

Findings show taletrectinib has superior efficacy, with higher response rates and lower risks of disease progression and mortality.

Both drugs have similar safety profiles, but crizotinib has more vision-related side effects. The study highlights the need for future phase three trials due to the rarity of this cancer type.